According to the latest filing from the U.S. Securities and Exchange Commission (SEC), biotechnology company Regenxbio Inc has officially signed a settlement and release agreement with pharmaceutical giant GlaxoSmithKline.

The agreement will take effect on March 18, 2026, marking a final resolution between both parties regarding the related disputes. The signing of this agreement terminates the previous legal disputes between the two parties, clearing obstacles for potential future cooperation. The document does not disclose the specific settlement amount or details of the agreement, but it clearly states that both parties agree to waive all claims against each other in this matter.